Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
← catalyst calendarNCT06413433 · readout ≤ 134 d
Sponsored by Axsome Therapeutics, Inc. (industry) · AXSM — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
450estimated
Sites
45
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-26 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2024-05-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Binge-Eating Disorder
Interventions
- Drug: Solriamfetol 150 mg
- Drug: Solriamfetol 300 mg
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from Baseline to Week 12 in number of binge eating episodes
measured 12 weeks
Permalink · AXSM's whole pipeline · Catalyst calendar · Every registered study · What changed